This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Max Planck Florida Institute For Neuroscience Welcomes Obama's BRAIN Project

National program creates opportunities to support the Max Planck Florida Institute's neural circuit research focused on Alzheimer's, Parkinson's, Epilepsy and other brain disorders

JUPITER, Fla., April 3, 2013 /PRNewswire-USNewswire/ --  The Obama administration formally announced its plan to fund the development of a comprehensive map of the brain's activity with a project called Brain Research Through Advancing Innovative Neurotechnologies (BRAIN), starting with an initial investment of $100 million in 2014. The 10-year research project is strongly supported by the Max Planck Florida Institute for Neuroscience in Jupiter, Fla. Scientists at the Institute claim this is a prime time to make such a strategic investment.

(Logo: )

"In the last five years, we've only just cracked open the door to technologies that make the impossible finally possible," said Dr. David Fitzpatrick, a former Professor of Neurobiology at the Duke University School of Medicine who is now the scientific director and CEO of the Max Planck Florida Institute for Neuroscience – the first Institute outside of Europe for Germany's renowned Max Planck Society. "You can't fix it if you don't know how it works. If we can't get to this detailed level of understanding of brain organization and activity, then we're not going to be in a position to effectively address brain disorders."

The Max Planck Florida Institute's nine distinct research groups are currently investigating the many remaining mysteries of the brain. Scientists are focused on neural circuits, the complex synaptic networks of the brain that hold the key to developing effective treatments for a host of neurological and psychiatric disorders and diseases, including Alzheimer's, Parkinson's, Huntington's, autism and schizophrenia. Dr. Fitzpatrick believes there will be great opportunities for his Institute to support and benefit from the new BRAIN research program.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs